<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Archiving and Interchange DTD v2.3 20070202//EN" "archivearticle.dtd"><article xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><front><journal-meta><journal-id journal-id-type="nlm-ta">BMC Cancer</journal-id><journal-title>BMC Cancer</journal-title><issn pub-type="epub">1471-2407</issn><publisher><publisher-name>BioMed Central</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">1471-2407-8-382</article-id><article-id pub-id-type="pmid">19099590</article-id><article-id pub-id-type="doi">10.1186/1471-2407-8-382</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group></article-categories><title-group><article-title>Genetic polymorphisms of <italic>RANTES, IL1-A, MCP-1 </italic>and <italic>TNF-A </italic>genes in patients with prostate cancer</article-title></title-group><contrib-group><contrib id="A1" equal-contrib="yes" contrib-type="author"><name><surname>S&#x000e1;enz-L&#x000f3;pez</surname><given-names>Pablo</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>pablosaenz-lopez@hotmail.com</email></contrib><contrib id="A2" equal-contrib="yes" contrib-type="author"><name><surname>Carretero</surname><given-names>Rafael</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>rafannel@hotmail.com</email></contrib><contrib id="A3" contrib-type="author"><name><surname>C&#x000f3;zar</surname><given-names>Jos&#x000e9; Manuel</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>cozarjm@yahoo.es</email></contrib><contrib id="A4" contrib-type="author"><name><surname>Romero</surname><given-names>Jos&#x000e9; Maria</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>josemariaromero@cofgranada.com</email></contrib><contrib id="A5" contrib-type="author"><name><surname>Canton</surname><given-names>Julia</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>julia.canton@gmail.com</email></contrib><contrib id="A6" contrib-type="author"><name><surname>Vilchez</surname><given-names>Jos&#x000e9; Ram&#x000f3;n</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>jrvilchez2000@gmail.com</email></contrib><contrib id="A7" contrib-type="author"><name><surname>Tallada</surname><given-names>Miguel</given-names></name><xref ref-type="aff" rid="I2">2</xref><email>miguel.tallada.sspa@juntadeandalucia.es</email></contrib><contrib id="A8" contrib-type="author"><name><surname>Garrido</surname><given-names>Federico</given-names></name><email>federico.garrido.sspa@juntadeandalucia.es</email></contrib><contrib id="A9" corresp="yes" contrib-type="author"><name><surname>Ruiz-Cabello</surname><given-names>Francisco</given-names></name><xref ref-type="aff" rid="I1">1</xref><email>fruizc@ugr.es</email></contrib></contrib-group><aff id="I1"><label>1</label>Servicio de An&#x000e1;lisis Cl&#x000ed;nicos e Inmunolog&#x000ed;a, Hospital Universitario Virgen de las Nieves, Granada, Spain</aff><aff id="I2"><label>2</label>Servicio de Urolog&#x000ed;a, Hospital Universitario Virgen de las Nieves, Granada, Spain</aff><pub-date pub-type="collection"><year>2008</year></pub-date><pub-date pub-type="epub"><day>19</day><month>12</month><year>2008</year></pub-date><volume>8</volume><fpage>382</fpage><lpage>382</lpage><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/382"/><history><date date-type="received"><day>19</day><month>3</month><year>2008</year></date><date date-type="accepted"><day>19</day><month>12</month><year>2008</year></date></history><permissions><copyright-statement>Copyright &#x000a9; 2008 S&#x000e1;enz-L&#x000f3;pez et al; licensee BioMed Central Ltd.</copyright-statement><copyright-year>2008</copyright-year><copyright-holder>S&#x000e1;enz-L&#x000f3;pez et al; licensee BioMed Central Ltd.</copyright-holder><license license-type="open-access" xlink:href="http://creativecommons.org/licenses/by/2.0"><p>This is an Open Access article distributed under the terms of the Creative Commons Attribution License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/2.0"/>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.</p><!--<rdf xmlns="http://web.resource.org/cc/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dc="http://purl.org/dc/elements/1.1" xmlns:dcterms="http://purl.org/dc/terms"><Work xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:dcterms="http://purl.org/dc/terms/" rdf:about=""><license rdf:resource="http://creativecommons.org/licenses/by/2.0"/><dc:type rdf:resource="http://purl.org/dc/dcmitype/Text"/><dc:author> S&#x000e1;enz-L&#x000f3;pez Pablo pablosaenz-lopez@hotmail.com </dc:author><dc:title> Genetic polymorphisms of RANTES, IL1-A, MCP-1 and TNF-A genes in patients with prostate cancer </dc:title><dc:date>2008</dc:date><dcterms:bibliographicCitation>BMC Cancer 8(1): 382-. (2008)</dcterms:bibliographicCitation><dc:identifier type="sici">1471-2407(2008)8:1&#x0003c;382&#x0003e;</dc:identifier><dcterms:isPartOf>urn:ISSN:1471-2407</dcterms:isPartOf><License rdf:about="http://creativecommons.org/licenses/by/2.0"><permits rdf:resource="http://web.resource.org/cc/Reproduction" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/Distribution" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Notice" xmlns=""/><requires rdf:resource="http://web.resource.org/cc/Attribution" xmlns=""/><permits rdf:resource="http://web.resource.org/cc/DerivativeWorks" xmlns=""/></License></Work></rdf>--></license></permissions><abstract><sec><title>Background</title><p>Inflammation has been implicated as an etiological factor in several human cancers, including prostate cancer. Allelic variants of the genes involved in inflammatory pathways are logical candidates as genetic determinants of prostate cancer risk. The purpose of this study was to investigate whether single nucleotide polymorphisms of genes that lead to increased levels of pro-inflammatory cytokines and chemokines are associated with an increased prostate cancer risk.</p></sec><sec sec-type="methods"><title>Methods</title><p>A case-control study design was used to test the association between prostate cancer risk and the polymorphisms <italic>TNF-A</italic>-308 A/G (rs 1800629), <italic>RANTES</italic>-403 G/A (rs 2107538), <italic>IL1-A</italic>-889 C/T (rs 1800587) and <italic>MCP-1 </italic>2518 G/A (rs 1024611) in 296 patients diagnosed with prostate cancer and in 311 healthy controls from the same area.</p></sec><sec><title>Results</title><p>Diagnosis of prostate cancer was significantly associated with <italic>TNF-A </italic>GA + AA genotype (OR, 1.61; 95% CI, 1.09&#x02013;2.64) and <italic>RANTES </italic>GA + AA genotype (OR, 1.44; 95% CI, 1.09&#x02013;2.38). A alleles in <italic>TNF-A </italic>and <italic>RANTES </italic>influenced prostate cancer susceptibility and acted independently of each other in these subjects. No epistatic effect was found for the combination of different polymorphisms studied. Finally, no overall association was found between prostate cancer risk and <italic>IL1-A </italic>or <italic>MCP-1 </italic>polymorphisms.</p></sec><sec><title>Conclusion</title><p>Our results and previously published findings on genes associated with innate immunity support the hypothesis that polymorphisms in proinflammatory genes may be important in prostate cancer development.</p></sec></abstract></article-meta></front><body><sec><title>Background</title><p>Chronic or recurrent inflammation is known to play a causative role in the promotion and progression of many human tumours, including cancers of the liver, oesophagus, stomach, large intestine and urinary bladder [<xref ref-type="bibr" rid="B1">1</xref>-<xref ref-type="bibr" rid="B3">3</xref>]. Chronic inflammation has also been implicated in the aetiology of prostate cancer [<xref ref-type="bibr" rid="B4">4</xref>-<xref ref-type="bibr" rid="B7">7</xref>]. Prostate cancer risk has been associated with sexually transmitted infections and prostatitis in some epidemiologic studies [<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B9">9</xref>], and its relationship with genetic polymorphisms in inflammatory cytokines has been explored in various case-control studies [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Chronic inflammation, alongside the intrinsic properties of pre-malignant cells and other determinants, may therefore be one of the driving forces of malignant transformation. Thus, numerous mediators released in dysregulated chronic inflammation have been found to promote cell growth and invasion, induce mutagenesis and increase angiogenicity [<xref ref-type="bibr" rid="B1">1</xref>]. By virtue of these properties, inflammatory mediators favour initiation of malignancy, and if sustained, may also promote progression. In general, many inflammatory conditions are characterized by the recruitment of inflammatory cells, predominantly macrophages, due to the wide variety of bioactive products they release. Cytokines and chemokines produced by activated innate immune cells are the most important components orchestrating the inflammatory-tumour-microenviroment [<xref ref-type="bibr" rid="B14">14</xref>]. Most studies have focussed on inflammatory chemokines that promote monocyte migration, primarily MCP-1 and also RANTES (regulated upon activation, normally T cell-expressed and presumably secreted) [<xref ref-type="bibr" rid="B15">15</xref>-<xref ref-type="bibr" rid="B17">17</xref>]. Full activation of NF-&#x003ba;B in inflammatory leukocytes resident in preneoplastic sites are likely to exacerbate local M1-inflammation (high TNF-A, high IL-1, high IL-12, low IL-10, low TGF-&#x003b2;) and favour tumourigenesis [<xref ref-type="bibr" rid="B18">18</xref>]. In particular, pro-inflammatory cytokines (e.g. IL-1 and TNF), can themselves affect cancer risk [<xref ref-type="bibr" rid="B1">1</xref>,<xref ref-type="bibr" rid="B5">5</xref>,<xref ref-type="bibr" rid="B8">8</xref>,<xref ref-type="bibr" rid="B19">19</xref>].</p><p>In the present investigation, we studied the role of several polymorphisms reported to have functional and biological relevance in the inflammatory process. The SNPs selected for study have all been found to influence the expression of their respective cytokine in vitro.</p><p>TNF is a key mediator of inflammation and may contribute to tumour initiation by stimulating production of genotoxic molecules, which can lead to DNA damage and mutations [<xref ref-type="bibr" rid="B20">20</xref>]. Inter-individual variations in TNF-A levels have been attributed to polymorphisms, notably the A allele at -308 (G/A) position in the promotor region of the <italic>TNF </italic>gene, which has been associated with higher <italic>TNF-A </italic>transcription levels [<xref ref-type="bibr" rid="B21">21</xref>] and an increased risk of several types of cancer [<xref ref-type="bibr" rid="B22">22</xref>]. However, findings on <italic>TNF-A </italic>polymorphisms in prostate cancer have been inconsistent [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. In fact, evaluation of genetic variation in cytokines and chemokines in relation to inflammation and cancer risk is a complex task. Thus, it is important to investigate the possible role of other genes involved in the inflammation pathway that might influence prostate cancer risk.</p><p>Proinflammatory cytokines IL-1A and IL-1B [<xref ref-type="bibr" rid="B23">23</xref>,<xref ref-type="bibr" rid="B24">24</xref>] are also produced by monocytes, macrophages and epithelial cells and exhibit similar biological characteristics to TNF-A, including participation in host response to microbial invasion, inflammation and tissue injury [<xref ref-type="bibr" rid="B20">20</xref>]. <italic>IL-1 </italic>polymorphisms have also been linked to gastric [<xref ref-type="bibr" rid="B25">25</xref>], hepatocellular [<xref ref-type="bibr" rid="B26">26</xref>], lung [<xref ref-type="bibr" rid="B27">27</xref>], colorectal [<xref ref-type="bibr" rid="B28">28</xref>], vulvar [<xref ref-type="bibr" rid="B29">29</xref>] and ovarian [<xref ref-type="bibr" rid="B30">30</xref>] cancers. Allele T of the <italic>IL1 (-</italic>889 C&#x0003e;T) polymorphism has been associated with high production of this cytokine [<xref ref-type="bibr" rid="B31">31</xref>].</p><p>RANTES chemokine is believed to play a role in antitumour immunity <italic>via </italic>immune cell recruitment [<xref ref-type="bibr" rid="B32">32</xref>]. Polymorphisms in <italic>RANTES </italic>have been associated with a higher risk of pancreatic cancer, supporting the hypothesis that proinflammatory gene polymorphisms, in combination with proinflammatory conditions, may influence the development of pancreatic cancer [<xref ref-type="bibr" rid="B33">33</xref>].</p><p>Finally, MCP-1, a member of the CC chemokine family, possesses chemotactic activity for monocytes and T lymphocytes [<xref ref-type="bibr" rid="B34">34</xref>,<xref ref-type="bibr" rid="B35">35</xref>] and has been proposed to play a key role in macrophage recruitment, expression of angiogenic factors and activation of matrix metalloproteinases in breast cancer patients. Genetic variants within regulatory regions of <italic>MCP-1 </italic>that affect transcription and protein production have been correlated with the risk of breast cancer metastasis [<xref ref-type="bibr" rid="B36">36</xref>]. This finding is consistent with the previously reported overexpression of <italic>MCP-1 </italic>in breast cancer tissue [<xref ref-type="bibr" rid="B37">37</xref>].</p><p>These cytokines and chemokines were selected for our study because they are released in response to various forms of cellular stress, including inflammation and carcinogen exposure. The objective of this study was to assess the influence of genetic polymorphism of <italic>RANTES, MCP-1, IL-1A </italic>and <italic>TNF-A </italic>on the risk of prostate cancer.</p></sec><sec sec-type="methods"><title>Methods</title><sec><title>Patient samples</title><p>The study included adult males with a recent diagnosis of prostate cancer (n = 296) referred to our hospital between 2002 and 2007. Clinical diagnosis of primary adenocarcinoma of the prostate was histopathologically confirmed after abnormal serum PSA findings and/or lower urinary tract symptoms. Patients were unrelated Caucasian men with a mean age of 67.4 &#x000b1; 5.8 yrs and mean PSA level of 31.6 &#x000b1; 5.7 (Table <xref ref-type="table" rid="T1">1</xref>). Healthy unrelated Caucasian men (n = 311) were enrolled as controls; these were recruited from among blood donors on the Spanish Bone Marrow Donor Registry of the same geographic region and with no history of prostate cancer according to Registry records. The mean of age of the controls was 44 &#x000b1; 11 yrs. The clinical characteristics of study participants are presented in Table <xref ref-type="table" rid="T1">1</xref>. The patients were classified according to their disease progression, Gleason score and PSA level. Peripheral blood samples were drawn from all participants into tubes containing K3-EDTA. All subjects were interviewed by a researcher and signed their informed consent to participation in the study, which was approved by the Ethics Committee of our hospital.</p><table-wrap position="float" id="T1"><label>Table 1</label><caption><p>Clinical caracteristics of prostate cancer patients.</p></caption><table frame="hsides" rules="groups"><thead><tr><td></td><td align="left"><bold>Case Subjects No</bold>.</td><td align="left"><bold>(%)</bold></td><td></td><td align="left"><bold>Case Subjects No</bold>.</td><td align="left"><bold>(%)</bold></td></tr></thead><tbody><tr><td align="left">Variables</td><td></td><td></td><td align="left">Variables</td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>Age at study</bold></td><td></td><td></td><td align="left"><bold>Gleason Score</bold></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">&#x0003c;60</td><td align="left">51</td><td></td><td align="left">&#x0003c;4</td><td align="left">15</td><td align="left">5</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">60&#x02013;69</td><td align="left">140</td><td></td><td align="left">4&#x02013;6</td><td align="left">122</td><td align="left">41.2</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">70&#x02013;79</td><td align="left">89</td><td></td><td align="left">7&#x02013;8</td><td align="left">133</td><td align="left">45</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">&#x0003e;80</td><td align="left">16</td><td></td><td align="left">9&#x02013;10</td><td align="left">26</td><td align="left">8.8</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>T Stage</bold></td><td></td><td></td><td align="left"><bold>Differential Grade</bold></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">T1</td><td align="left">25</td><td align="left">8.5</td><td align="left">1</td><td align="left">25</td><td align="left">8.5</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">T2</td><td align="left">112</td><td align="left">37.8</td><td align="left">2</td><td align="left">245</td><td align="left">82.7</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">T3</td><td align="left">111</td><td align="left">37.5</td><td align="left">3</td><td align="left">26</td><td align="left">8.8</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">T4</td><td align="left">48</td><td align="left">16.2</td><td align="left"><bold>PSA levels, ng/ml</bold></td><td></td><td></td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>N Stage</bold></td><td></td><td></td><td align="left">&#x0003c;10</td><td align="left">69</td><td align="left">23.3</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">N0</td><td align="left">187</td><td align="left">63.2</td><td align="left">10&#x02013;19.99</td><td align="left">68</td><td align="left">23</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">N1</td><td align="left">109</td><td align="left">36.8</td><td align="left">20&#x02013;20.99</td><td align="left">39</td><td align="left">13.2</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left"><bold>M Stage</bold></td><td></td><td></td><td align="left">30&#x02013;30.99</td><td align="left">20</td><td align="left">6.7</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">M0</td><td align="left">226</td><td align="left">76.3</td><td align="left">40&#x02013;40.99</td><td align="left">18</td><td align="left">6</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td align="left">M1</td><td align="left">70</td><td align="left">23.7</td><td align="left">50&#x02013;50.99</td><td align="left">22</td><td align="left">7.4</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="left">60&#x02013;99.99</td><td align="left">39</td><td align="left">13.2</td></tr><tr><td colspan="6"><hr></hr></td></tr><tr><td></td><td></td><td></td><td align="left">&#x0003e;100</td><td align="left">21</td><td align="left">7</td></tr></tbody></table></table-wrap></sec><sec><title>DNA samples and genotyping</title><p>Total genomic DNA was isolated from peripheral blood of prostate cancer patients and healthy controls using the QIAamp DNA Mini kit. SNPs samples were genotyped by means of a Taqman 5' allelic discrimination assay. The PCR and genotype of each sample was automatically attributed by measuring the allelic specific fluorescence on 500 PCR-REAL TIME Sequence Detection System using SDS 2.2.1 software for allelic discrimination (Applied Biosystems, Foster City, CA, USA). Single nucleotide polymorphism amplification assays were used according to the manufacturer's instructions. Briefly, 10 ng of sample DNA(1 &#x003bc;l) were placed in 4 &#x003bc;l of reaction solution containing: 2.5 &#x003bc;l of the 2&#x000d7; TaqMan<sup>&#x000ae; </sup>Universal PCR Mix (Applied Biosystems), 0.25 &#x003bc;l of predevel ped assay reagent from the SNP genotyping product(20&#x000d7;) (Applied Biosystems) containing two primers and two MGB-Taqman probes, and 1.25 &#x003bc;l of distilled water. Reaction conditions of the PCR were: preincubation at 50&#x000b0;C for 2 min and at 95&#x000b0;C for 10 min, followed by 40 cycles of 95&#x000b0;C, 15 s; 60&#x000b0;C, 1 min. The polymorphisms studied were: <italic>TNF</italic>-308 A/G (rs 1800629) SNP, <italic>RANTES</italic>-403 G/A (rs 2107538) SNP, <italic>IL-1A</italic>-889 C/T (rs 1800587) SNP, and <italic>MCP-1 </italic>2518 G/A (rs 1024611) SNP. We studied the polymorphism in the promoter region that affects its transcriptions. Thus, in <italic>RANTES</italic>, polymorphism A/G in region -403 of the promoter was studied; the A allele is associated with higher transcription [<xref ref-type="bibr" rid="B38">38</xref>]. In <italic>MCP-1</italic>, polymorphism A/G in region -2518 of the promoter was studied; the G allele produces much higher <italic>MCP-1 </italic>expression [<xref ref-type="bibr" rid="B39">39</xref>]. In <italic>IL1-A</italic>, polymorphism C/T in region -889 of the promoter was studied; the T allele causes higher <italic>IL1-A </italic>expression[<xref ref-type="bibr" rid="B31">31</xref>]. In <italic>TNF-A</italic>, polymorphism G/A of region -308 of the promoter was studied; the A allele produces higher <italic>TNF-A </italic>expression [<xref ref-type="bibr" rid="B40">40</xref>].</p></sec><sec><title>Statistical analyses</title><p>Data were compiled according to the genotype and allele frequencies estimated from the observed number of each specific allele. SNPs allele frequencies were tested against Hardy-Weinberg equilibrium by comparing observed with expected genotype frequencies using a &#x003c7;<sup>2 </sup>test. The present study has a power higher than 95% to detect an Odds Ratio (OR) of 2 in all analyses (measured by Episheet programme). Genotype frequencies were compared in 2 &#x000d7; 2 tables with the &#x003c7;<sup>2 </sup>test. The strength of association was estimated by calculating ORs with 95% CI and p values. Binary logistic regression analysis was used to confirm differences in SNP frequencies between cases and controls. Interaction analysis was calculated by logistic binary regression. The SPSS v.15.0 software package was used for the statistical analyses.</p></sec></sec><sec><title>Results</title><p>The study included 296 patients recently diagnosed with prostate cancer and 311 blood donors (controls). Table <xref ref-type="table" rid="T2">2</xref> shows the genotype and allelic distributions of the polymorphisms in cases and controls, with estimated ORs. None of the SNP genotype frequencies deviated from Hardy-Weinberg equilibrium, and the distributions of alleles in the control group were in agreement with findings in other Spanish Caucasian populations [<xref ref-type="bibr" rid="B41">41</xref>]. Polymorphisms could sometimes not be genotyped because of PCR amplification problems, explaining discrepancies in the numbers of cases among groups. Associations were obtained by comparing with the control population (not age-matched). Comparison of <italic>TNF-A </italic>promoter polymorphisms between patients and controls revealed statistically significant differences in genotype distribution for locus -308, with a higher frequency of A carriers (AA/AG) in patients than in controls (OR = 1.61; 95% CI: 1.09&#x02013;2.64 <italic>p </italic>= <italic>0.017</italic>). Patients also showed a higher frequency of A allele in the <italic>RANTES </italic>-403 G/A polymorphism versus controls (OR = 1.44; 95% CI: 1.09&#x02013;2.38 <italic>p </italic>= <italic>0.039</italic>). In contrast, <italic>MCP-1 </italic>2518 G/A and <italic>IL-1 A</italic>- 889 T allele genotypes showed no significant differences between prostate cancer and control groups (Table <xref ref-type="table" rid="T2">2</xref>), suggesting that these two genotypes may not play a role in susceptibility to prostate cancer.</p><table-wrap position="float" id="T2"><label>Table 2</label><caption><p>Statistical analysis of allele and genotype distributions of <italic>IL1A, MCP-1, RANTES </italic>and <italic>TNF-A </italic>polymorphisms.</p></caption><table frame="hsides" rules="groups"><thead><tr><td align="left"><bold>Genotype frequencies</bold></td><td align="center" colspan="2"><bold>Control</bold><break/><bold>n = 311</bold></td><td align="left" colspan="2"><bold>Case</bold><break/><bold>n = 298</bold></td><td align="left"><bold>Genotype results</bold></td><td align="left"><bold>p value</bold></td><td align="left"><bold>OR</bold></td><td align="left"><bold>95% confidence interval</bold></td><td align="left"><bold>Interaction an&#x000e1;lysis</bold></td></tr><tr><td></td><td colspan="4"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td></td><td align="center"><bold>n</bold></td><td align="center"><bold>%</bold></td><td align="left"><bold>n</bold></td><td align="left"><bold>%</bold></td><td></td><td></td><td></td><td></td><td></td></tr></thead><tbody><tr><td align="left"><italic>Il-1 CC</italic></td><td align="center">152</td><td align="center">50.2</td><td align="left">133</td><td align="left">44.9</td><td align="left">Il-1 CT/TT versus CC [<xref ref-type="bibr" rid="B25">25</xref>]</td><td align="left">0.200</td><td align="left">1.23</td><td align="left">0.89 &#x02013; 1.82</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>Il-1 CT/TT</italic></td><td align="center">151</td><td align="center">49.8</td><td align="left">163</td><td align="left">55.1</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>TNF-alpha GG</italic></td><td align="center">256</td><td align="center">82.6</td><td align="left">221</td><td align="left">74.7</td><td align="left">TNF-alpha AG/AA versus GG [<xref ref-type="bibr" rid="B13">13</xref>]</td><td align="left">0.017</td><td align="left">1.61</td><td align="left">1.09 &#x02013; 2.64</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>TNF-alpha AG/AA</italic></td><td align="center">54</td><td align="center">17.4</td><td align="left">75</td><td align="left">25.3</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>MCP-1 AA</italic></td><td align="center">178</td><td align="center">57.2</td><td align="left">174</td><td align="left">58.4</td><td align="left">MCP-1 AG/GG versus AA [<xref ref-type="bibr" rid="B27">27</xref>]</td><td align="left">0.770</td><td align="left">0.95</td><td align="left">0.66 &#x02013; 1.33</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>MCP-1 AG/GG</italic></td><td align="center">133</td><td align="center">42.8</td><td align="left">124</td><td align="left">41.6</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>RANTES GG</italic></td><td align="center">221</td><td align="center">72.5</td><td align="left">192</td><td align="left">64.6</td><td align="left">RANTES AG/AA versus GG [<xref ref-type="bibr" rid="B16">16</xref>]</td><td align="left">0.039</td><td align="left">1.44</td><td align="left">1.09 &#x02013; 2.38</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>RANTES AG/AA</italic></td><td align="center">84</td><td align="center">27.5</td><td align="left">105</td><td align="left">35.4</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td></td><td></td><td></td><td></td><td></td><td align="left">TNF-alpha AG/AA and RANTES AG/AA</td><td align="left">0.012</td><td align="left">2.45</td><td align="left">1.22 &#x02013; 4.94</td><td align="left">0.416</td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><bold>Allele frequencies</bold></td><td></td><td></td><td></td><td></td><td align="left"><bold>Allele results</bold></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>Il-1 C</italic></td><td align="center">426</td><td align="center">70.3</td><td align="left">401</td><td align="left">67.5</td><td align="left">Il-1 C versus Il-1 T</td><td align="left">0.297</td><td align="left">1.14</td><td align="left">0.89&#x02013;1.46</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>Il-1 T</italic></td><td align="center">180</td><td align="center">29.7</td><td align="left">193</td><td align="left">32.5</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>TNF-alpha G</italic></td><td align="center">564</td><td align="center">90.97</td><td align="left">512</td><td align="left">86.5</td><td align="left">TNF-alpha G versus A</td><td align="left">0.013</td><td align="left">1.57</td><td align="left">1.10&#x02013;2.26</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>TNF-alpha A</italic></td><td align="center">56</td><td align="center">9.03</td><td align="left">80</td><td align="left">13.5</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>MCP-1 A</italic></td><td align="center">479</td><td align="center">77.01</td><td align="left">448</td><td align="left">75.2</td><td align="left">MCP-1 A versus G</td><td align="left">0.451</td><td align="left">1.11</td><td align="left">0.85&#x02013;1.44</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>MCP-1 G</italic></td><td align="center">143</td><td align="center">22.99</td><td align="left">148</td><td align="left">24.8</td><td></td><td></td><td></td><td></td><td></td></tr><tr><td colspan="10"><hr></hr></td></tr><tr><td align="left"><italic>RANTES G</italic></td><td align="center">522</td><td align="center">85.57</td><td align="left">478</td><td align="left">80.5</td><td align="left">RANTES G versus A</td><td align="left">0.018</td><td align="left">1.44</td><td align="left">1.03&#x02013;1.95</td><td></td></tr><tr><td colspan="5"><hr></hr></td><td></td><td></td><td></td><td></td><td></td></tr><tr><td align="left"><italic>RANTES A</italic></td><td align="center">88</td><td align="center">14.43</td><td align="left">116</td><td align="left">19.5</td><td></td><td></td><td></td><td></td><td></td></tr></tbody></table></table-wrap><p>We stratified the data, grouping subjects according to their carrier status for <italic>IL1-A </italic>allele T, <italic>TNF-A </italic>allele A, <italic>RANTES </italic>allele A and <italic>MCP-1 </italic>allele G. In logistic regression analyses, no significant association with prostate cancer risk was found for <italic>IL1 </italic>or <italic>MCP-1 </italic>allele carrier status, but subjects with AG or AA genotypes for <italic>TNF-A </italic>or <italic>RANTES </italic>had increased prostate cancer risk versus those with GG genotype (Table <xref ref-type="table" rid="T2">2</xref>). The combination of the A allele of <italic>TNF </italic>and <italic>RANTES </italic>markedly increased this risk (OR, 2.45; 95% CI, 1.22 &#x02013; 4.94, <italic>p </italic>= <italic>0.012</italic>), although no epistatic effect (<italic>p </italic>= <italic>0.416</italic>) was observed between these polymorphisms. SNP genotypes were also compared within the patient group and stratified according to tumour stage and serum PSA level (Table <xref ref-type="table" rid="T1">1</xref>) to determine whether the genotypes influenced these indicators. No significant associations were observed.</p></sec><sec><title>Discussion</title><p>Several polymorphisms have been associated with the severity of or susceptibility to numerous inflammatory diseases. In this case-control study, we investigated the association between polymorphisms in cytokine/chemokine genes (<italic>TNF-A </italic>-308 G/A, <italic>RANTES</italic>-403 G/A, <italic>IL-1A </italic>-889 C/T and <italic>MCP-1 </italic>2518 G/A) and prostate cancer risk. Reports on <italic>TNF-A </italic>gene polymorphisms and prostate cancer have been controversial [<xref ref-type="bibr" rid="B10">10</xref>-<xref ref-type="bibr" rid="B13">13</xref>]. Our results suggest that the A allele, associated with a high production of TNF-A, is linked to an increased risk for prostate cancer. TNF-A, a major factor in the inflammation response, has been related to many types of cancer, e.g., T-cell large granular lymphocyte leukaemia [<xref ref-type="bibr" rid="B42">42</xref>], cholestatic liver cancer, multiple myeloma, bladder cancer, hepatocellular carcinoma, gastric cancer and breast cancer [<xref ref-type="bibr" rid="B22">22</xref>]. However, no association has been described with nasopharyngeal carcinoma [<xref ref-type="bibr" rid="B43">43</xref>] or cervix carcinoma [<xref ref-type="bibr" rid="B44">44</xref>]. Discrepancies in some previously published results for <italic>TNF-A </italic>gene polymorphisms in prostate cancer may be related to the modest risk found. Inflammation is a highly complex process that involves hundreds of genes. The fact that numerous gene polymorphisms contribute to the inflammatory response adds further complexity to the analysis of a specific polymorphism, because each individual gene is likely to contribute only modestly to the risk. Thus, TNF-A may interact in important ways with multiple cytokine/chemokines involved in inflammation pathways that also display genetic variation.</p><p>The discrepant results may be explained by the effects of genetic heterogeneity and different gene-environment interactions. Although the distribution of -308A <italic>TNF-A </italic>has been found to vary among control groups due to ethnic variations [<xref ref-type="bibr" rid="B44">44</xref>], the distribution of the allelic frequencies in our study was similar to a recent report [<xref ref-type="bibr" rid="B13">13</xref>]. The influence of other (non-inflammation-related) genes or environmental factors is more likely to account for differences. Thus, there is evidence that prostate cancer has a complex and multifactorial aetiology, which might explain discrepancies in the attribution of prostate cancer risk to a single SNP [<xref ref-type="bibr" rid="B45">45</xref>]. Furthermore, discrepant results between the NorthAmerican [<xref ref-type="bibr" rid="B13">13</xref>] and the present study might be influenced by differences in diet, lifestyle and NSAID use between the study populations.</p><p>In this context, differences in <italic>NF-kB </italic>polymorphism were reported between Spanish and North American groups in association with ulcerative colitis [<xref ref-type="bibr" rid="B46">46</xref>]. Finally, a Sweden Study [<xref ref-type="bibr" rid="B47">47</xref>,<xref ref-type="bibr" rid="B48">48</xref>] found that increased risk for this type of tumour is probably also influenced by other genes that regulate inflammation (Toll-like receptor) and modify individual susceptibility to prostate cancer. The combined effect of several polymorphism loci is likely to markedly increase the risk of prostate cancer.</p><p>Gene-cluster polymorphisms in the <italic>interleukin-1 </italic>(<italic>IL1B</italic>) are associated with an increased risk of gastric and other types of cancer [<xref ref-type="bibr" rid="B25">25</xref>,<xref ref-type="bibr" rid="B30">30</xref>,<xref ref-type="bibr" rid="B49">49</xref>]. However, no associations have been found between polymorphisms in the IL1 gene cluster (<italic>IL1A, IL1B </italic>and <italic>IL1R</italic>) and ovarian or breast cancer [<xref ref-type="bibr" rid="B50">50</xref>,<xref ref-type="bibr" rid="B51">51</xref>]. Other authors reported no overall association between IL-1 polymorphisms and gastric cancer [<xref ref-type="bibr" rid="B52">52</xref>], and the reason for these different findings are unclear. The present case-control study in Caucasian men found no significant effect of <italic>IL1A </italic>(-889 C&#x0003e;T) gene polymorphisms on prostate cancer risk.</p><p>Chemokines are also expressed in inflammation, attracting and recruiting populations of immune effector cells to injury or infection sites, and the relationship between prostate cancer risk and polymorphisms of <italic>RANTES </italic>and <italic>MCP-1 </italic>was investigated in this study. No link with the <italic>MCP-1 </italic>polymorphism was observed, but a significant association was found between the A allele of <italic>RANTES </italic>and prostate cancer risk (<italic>p </italic>= <italic> 0.039</italic>). Allele A in <italic>RANTES </italic>is associated with increased transcription, which is related to inflammation and antitumour immunity <italic>via </italic>immune cell recruitment [<xref ref-type="bibr" rid="B53">53</xref>]. The allele A of <italic>RANTES </italic>and <italic>TNF-A </italic>has been associated with pancreatitis, especially as a possible early sign of pancreatic cancer [<xref ref-type="bibr" rid="B33">33</xref>]. In our study, the same alleles (<italic>TNF-A </italic>and <italic>RANTES</italic>) were also associated with a higher prostate cancer risk. Interestingly, the simultaneous presence of allele A of both genes promotes a higher risk (OR = 2.45, <italic>p </italic>= <italic>0.012</italic>) of cancer, but the interaction analysis showed no epistatic interaction between them (<italic>p </italic>= <italic> 0.416</italic>), indicating that their effects were additive. Finally, our study has some evident limitations and false positive results cannot be ruled out: thus, size of the study population is relatively small, aged-matched controls were not used and a possible bias corresponding to age cannot be excluded. However, even if we would have used a totally age-matched control subjects, our results would have been with even higher significance, because in this control group we cannot rule out a possibility that some of the younger control subjects may develop prostate cancer later in their life. In addition, there was no difference found between our control subjects and those used from our geographic area in a study of age-related diseases [<xref ref-type="bibr" rid="B54">54</xref>,<xref ref-type="bibr" rid="B55">55</xref>]. In general, we would like to comment that the influence of age on the immune gene polymorphism remains controversial. Some publications indicate that there are no differences in genotype distribution between older and younger controls [<xref ref-type="bibr" rid="B56">56</xref>], whereas others have reported an age-dependent difference in polymorphism of certain genes [<xref ref-type="bibr" rid="B57">57</xref>].</p><p>There is a need for studies of larger patient groups, including other potential functional polymorphisms in linkage disequilibrium to determine the role of these polymorphisms in prostate cancer.</p></sec><sec><title>Conclusion</title><p>In conclusion, our data suggest an important role for <italic>TNF-A </italic>and <italic>RANTES </italic>polymorphisms in prostate cancer, as observed in many other types of cancer. Other genetic polymorphisms involved in innate immunity and chronic inflammation have been associated with prostate cancer [<xref ref-type="bibr" rid="B48">48</xref>], and the present findings support the hypothesis that the inflammatory process may constitute an important step in the initiation and promotion of prostate cancer.</p></sec><sec><title>Competing interests</title><p>The authors declare that they have no competing interests.</p></sec><sec><title>Authors' contributions</title><p>PSL, JC and RC performed analyses, managed the storage of blood samples and performed genotyping. JMR and JRV performed statistical analyses and programming. JMC and MT were responsible for data collection and manuscript editing. FG and FRC conceived of the study, participated in its design and coordination and drafted the manuscript. All authors have read and approved the final manuscript</p></sec><sec><title>Pre-publication history</title><p>The pre-publication history for this paper can be accessed here:</p><p><ext-link ext-link-type="uri" xlink:href="http://www.biomedcentral.com/1471-2407/8/382/prepub"/></p></sec></body><back><ack><sec><title>Acknowledgements</title><p>We would like to thank Ms. Anabel Rodr&#x000ed;guez and Eva Garc&#x000ed;a for technical assistance. This study was supported by grants from the Fondo de Investigaciones Sanitarias (FIS), Red Genomica del Cancer (RETIC RD 06/0020), Plan Andaluz de Investigacion (Group CTS 143), Consejeria Andaluz de Salud (SAS), Proyecto de Excelencia de Consejeria de Innovacion (CTS 695), Proyecto de investigacion I+D (SAF 2007-63262) in Spain; and from the Integrated European Cancer Immunotherapy project (OJ2004/C158, 518234).</p></sec></ack><ref-list><ref id="B1"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Coussens</surname><given-names>LM</given-names></name><name><surname>Werb</surname><given-names>Z</given-names></name></person-group><article-title>Inflammation and cancer</article-title><source>Nature</source><year>2002</year><volume>420</volume><fpage>860</fpage><lpage>867</lpage><pub-id pub-id-type="pmid">12490959</pub-id><pub-id pub-id-type="doi">10.1038/nature01322</pub-id></citation></ref><ref id="B2"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Balkwill</surname><given-names>F</given-names></name><name><surname>Charles</surname><given-names>KA</given-names></name><name><surname>Mantovani</surname><given-names>A</given-names></name></person-group><article-title>Smoldering and polarized inflammation in the initiation and promotion of malignant disease</article-title><source>Cancer Cell</source><year>2005</year><volume>7</volume><fpage>211</fpage><lpage>217</lpage><pub-id pub-id-type="pmid">15766659</pub-id><pub-id pub-id-type="doi">10.1016/j.ccr.2005.02.013</pub-id></citation></ref><ref id="B3"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ben-Baruch</surname><given-names>A</given-names></name></person-group><article-title>Inflammation-associated immune suppression in cancer: the roles played by cytokines, chemokines and additional mediators</article-title><source>Semin Cancer Biol</source><year>2006</year><volume>16</volume><fpage>38</fpage><lpage>52</lpage><pub-id pub-id-type="pmid">16139507</pub-id><pub-id pub-id-type="doi">10.1016/j.semcancer.2005.07.006</pub-id></citation></ref><ref id="B4"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Marchi</surname><given-names>VL</given-names></name><name><surname>Epstein</surname><given-names>JI</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name></person-group><article-title>Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis</article-title><source>Am J Pathol</source><year>1999</year><volume>155</volume><fpage>1985</fpage><lpage>1992</lpage><pub-id pub-id-type="pmid">10595928</pub-id></citation></ref><ref id="B5"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Sutcliffe</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name></person-group><article-title>Inflammation in prostate carcinogenesis</article-title><source>Nature Rev</source><year>2007</year><volume>7</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/nrc2090</pub-id></citation></ref><ref id="B6"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>WG</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name></person-group><article-title>Prostate cancer</article-title><source>N Engl J Med</source><year>2003</year><volume>349</volume><fpage>366</fpage><lpage>381</lpage><pub-id pub-id-type="pmid">12878745</pub-id><pub-id pub-id-type="doi">10.1056/NEJMra021562</pub-id></citation></ref><ref id="B7"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>De Marzo</surname><given-names>AM</given-names></name></person-group><article-title>Epidemiology of inflammation and prostate cancer</article-title><source>J Urol</source><year>2004</year><volume>171</volume><fpage>S36</fpage><lpage>S40</lpage><pub-id pub-id-type="pmid">14713751</pub-id><pub-id pub-id-type="doi">10.1097/01.ju.0000108131.43160.77</pub-id></citation></ref><ref id="B8"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>LK</given-names></name><name><surname>Lynch</surname><given-names>CF</given-names></name><name><surname>Torner</surname><given-names>JC</given-names></name></person-group><article-title>Epidemiologic association between prostatitis and prostate cancer</article-title><source>Urology</source><year>2002</year><volume>60</volume><fpage>78</fpage><lpage>83</lpage><pub-id pub-id-type="pmid">12100928</pub-id><pub-id pub-id-type="doi">10.1016/S0090-4295(02)01637-0</pub-id></citation></ref><ref id="B9"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dennis</surname><given-names>LK</given-names></name><name><surname>Dawson</surname><given-names>DV</given-names></name></person-group><article-title>Meta-analysis of measures of sexual activity and prostate cancer</article-title><source>Epidemiology</source><year>2002</year><volume>13</volume><fpage>72</fpage><lpage>79</lpage><pub-id pub-id-type="pmid">11805589</pub-id><pub-id pub-id-type="doi">10.1097/00001648-200201000-00012</pub-id></citation></ref><ref id="B10"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oh</surname><given-names>BR</given-names></name><name><surname>Sasaki</surname><given-names>M</given-names></name><name><surname>Perinchery</surname><given-names>G</given-names></name><name><surname>Ryu</surname><given-names>SB</given-names></name><name><surname>Park</surname><given-names>YI</given-names></name><name><surname>Carroll</surname><given-names>P</given-names></name><name><surname>Dahiya</surname><given-names>R</given-names></name></person-group><article-title>Frequent genotype changes at -308, and 488 regions of the tumor necrosis factor-alpha (TNF-alpha) gene in patients with prostate cancer</article-title><source>J Urol</source><year>2000</year><volume>163</volume><fpage>1584</fpage><lpage>1587</lpage><pub-id pub-id-type="pmid">10751892</pub-id><pub-id pub-id-type="doi">10.1016/S0022-5347(05)67683-5</pub-id></citation></ref><ref id="B11"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname><given-names>HC</given-names></name><name><surname>Chang</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>HY</given-names></name><name><surname>Tsai</surname><given-names>FJ</given-names></name><name><surname>Tsai</surname><given-names>JJ</given-names></name><name><surname>Chen</surname><given-names>WC</given-names></name></person-group><article-title>p53 gene codon 72 polymorphism but not tumor necrosis factor-alpha gene is associated with prostate cancer</article-title><source>Urol Int</source><year>2004</year><volume>73</volume><fpage>41</fpage><lpage>46</lpage><pub-id pub-id-type="pmid">15263792</pub-id><pub-id pub-id-type="doi">10.1159/000078803</pub-id></citation></ref><ref id="B12"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>McCarron</surname><given-names>SL</given-names></name><name><surname>Edwards</surname><given-names>S</given-names></name><name><surname>Evans</surname><given-names>PR</given-names></name><name><surname>Gibbs</surname><given-names>R</given-names></name><name><surname>Dearnaley</surname><given-names>DP</given-names></name><name><surname>Dowe</surname><given-names>A</given-names></name><name><surname>Southgate</surname><given-names>C</given-names></name><name><surname>Easton</surname><given-names>DF</given-names></name><name><surname>Eeles</surname><given-names>RA</given-names></name><name><surname>Howell</surname><given-names>WM</given-names></name></person-group><article-title>Influence of cytokine gene polymorphisms on the development of prostate cancer</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>3369</fpage><lpage>3372</lpage><pub-id pub-id-type="pmid">12067976</pub-id></citation></ref><ref id="B13"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Danforth</surname><given-names>KN</given-names></name><name><surname>Rodriguez</surname><given-names>C</given-names></name><name><surname>Hayes</surname><given-names>RB</given-names></name><name><surname>Sakoda</surname><given-names>LC</given-names></name><name><surname>Huang</surname><given-names>WY</given-names></name><name><surname>Yu</surname><given-names>K</given-names></name><name><surname>Calle</surname><given-names>EE</given-names></name><name><surname>Jacobs</surname><given-names>EJ</given-names></name><name><surname>Chen</surname><given-names>BE</given-names></name><name><surname>Andriole</surname><given-names>GL</given-names></name><name><surname>Figueroa</surname><given-names>JD</given-names></name><name><surname>Yeager</surname><given-names>M</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Michaud</surname><given-names>DS</given-names></name><name><surname>Chanock</surname><given-names>SJ</given-names></name><name><surname>Thun</surname><given-names>MJ</given-names></name><name><surname>Hsing</surname><given-names>AW</given-names></name></person-group><article-title>TNF polymorphisms and prostate cancer risk</article-title><source>Prostate</source><year>2008</year><volume>68</volume><fpage>400</fpage><lpage>407</lpage><pub-id pub-id-type="pmid">18196539</pub-id><pub-id pub-id-type="doi">10.1002/pros.20694</pub-id></citation></ref><ref id="B14"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lin</surname><given-names>WW</given-names></name><name><surname>Karin</surname><given-names>M</given-names></name></person-group><article-title>A cytokine-mediated link between innate immunity, inflammation, and cancer</article-title><source>J Clin Invest</source><year>2007</year><volume>117</volume><fpage>1175</fpage><lpage>1183</lpage><pub-id pub-id-type="pmid">17476347</pub-id><pub-id pub-id-type="doi">10.1172/JCI31537</pub-id></citation></ref><ref id="B15"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Conti</surname><given-names>I</given-names></name><name><surname>Rollins</surname><given-names>BJ</given-names></name></person-group><article-title>CCL2 (monocyte chemoattractant protein-1) and cancer</article-title><source>Semin Cancer Biol</source><year>2004</year><volume>14</volume><fpage>149</fpage><pub-id pub-id-type="pmid">15246049</pub-id><pub-id pub-id-type="doi">10.1016/j.semcancer.2003.10.009</pub-id></citation></ref><ref id="B16"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ueno</surname><given-names>T</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name><name><surname>Saji</surname><given-names>H</given-names></name><name><surname>Muta</surname><given-names>M</given-names></name><name><surname>Bando</surname><given-names>H</given-names></name><name><surname>Kuroi</surname><given-names>K</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Inadera</surname><given-names>H</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name></person-group><article-title>Significance of macrophage chemoattractant protein-1 in macrophage recruitment, angiogenesis, and survival in human breast cancer</article-title><source>Clin Cancer Res</source><year>2000</year><volume>6</volume><fpage>3282</fpage><pub-id pub-id-type="pmid">10955814</pub-id></citation></ref><ref id="B17"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Azenshtein</surname><given-names>E</given-names></name><name><surname>Luboshits</surname><given-names>G</given-names></name><name><surname>Shina</surname><given-names>S</given-names></name><name><surname>Neumark</surname><given-names>E</given-names></name><name><surname>Shahbazian</surname><given-names>D</given-names></name><name><surname>Weil</surname><given-names>M</given-names></name><name><surname>Wigler</surname><given-names>N</given-names></name><name><surname>Keydar</surname><given-names>I</given-names></name><name><surname>Ben-Baruch</surname><given-names>A</given-names></name></person-group><article-title>The CC chemokine RANTES in breast carcinoma progression: regulation of expression and potential mechanisms of promalignant activity</article-title><source>Cancer Res</source><year>2002</year><volume>62</volume><fpage>1093</fpage><pub-id pub-id-type="pmid">11861388</pub-id></citation></ref><ref id="B18"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Antonio</surname><given-names>Sica</given-names></name><name><surname>Paola</surname><given-names>Allavena</given-names></name><name><surname>Alberto</surname><given-names>Mantovani</given-names></name></person-group><article-title>Cancer related inflammation: The macrophage connection</article-title><source>Cancer Leters</source><year>2008</year><volume>264</volume><fpage>299</fpage><lpage>310</lpage><pub-id pub-id-type="doi">10.1016/j.canlet.2008.01.041</pub-id></citation></ref><ref id="B19"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>De Marzo</surname><given-names>AM</given-names></name><name><surname>Platz</surname><given-names>EA</given-names></name><name><surname>Sutcliffe</surname><given-names>S</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gronberg</surname><given-names>H</given-names></name><name><surname>Drake</surname><given-names>CG</given-names></name><name><surname>Nakai</surname><given-names>Y</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Nelson</surname><given-names>WG</given-names></name></person-group><article-title>Inflammation in prostate carcinogenesis</article-title><source>Nature Rev</source><year>2007</year><volume>7</volume><fpage>256</fpage><lpage>269</lpage><pub-id pub-id-type="doi">10.1038/nrc2090</pub-id></citation></ref><ref id="B20"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hussain</surname><given-names>SP</given-names></name><name><surname>Hofseth</surname><given-names>LJ</given-names></name><name><surname>Harris</surname><given-names>CC</given-names></name></person-group><article-title>Radical causes of cancer</article-title><source>Nat Rev Cancer</source><year>2003</year><volume>3</volume><fpage>276</fpage><lpage>285</lpage><pub-id pub-id-type="pmid">12671666</pub-id><pub-id pub-id-type="doi">10.1038/nrc1046</pub-id></citation></ref><ref id="B21"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>McDowell</surname><given-names>TL</given-names></name><name><surname>McDevitt</surname><given-names>HO</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3195</fpage><lpage>3199</lpage><pub-id pub-id-type="pmid">9096369</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.7.3195</pub-id></citation></ref><ref id="B22"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mocellin</surname><given-names>S</given-names></name><name><surname>Rossi</surname><given-names>CR</given-names></name><name><surname>Pilati</surname><given-names>P</given-names></name><name><surname>Nitti</surname><given-names>D</given-names></name></person-group><article-title>Tumor necrosis factor, cancer and anticancer therapy</article-title><source>Cytokine Growth Factor Rev</source><year>2005</year><volume>16</volume><fpage>35</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">15733831</pub-id><pub-id pub-id-type="doi">10.1016/j.cytogfr.2004.11.001</pub-id></citation></ref><ref id="B23"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dinarello</surname><given-names>CA</given-names></name></person-group><article-title>The interleukin-1 family: 10 years of discovery</article-title><source>FASEB J</source><year>1994</year><volume>8</volume><fpage>1314</fpage><lpage>1325</lpage><pub-id pub-id-type="pmid">8001745</pub-id></citation></ref><ref id="B24"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Arend</surname><given-names>WP</given-names></name></person-group><article-title>Interleukin 1 receptor antagonist. A new member of the interleukin 1 family</article-title><source>J Clin Invest</source><year>1991</year><volume>88</volume><fpage>1445</fpage><lpage>1451</lpage><pub-id pub-id-type="pmid">1834696</pub-id><pub-id pub-id-type="doi">10.1172/JCI115453</pub-id></citation></ref><ref id="B25"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name><name><surname>McColl</surname><given-names>KE</given-names></name><name><surname>Bream</surname><given-names>JH</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Herrera</surname><given-names>J</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>CC</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lanyon</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Rabkin</surname><given-names>CS</given-names></name></person-group><article-title>Interleukin-1 polymorphisms associated with increased risk of gastric cancer</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">10746728</pub-id><pub-id pub-id-type="doi">10.1038/35006081</pub-id></citation></ref><ref id="B26"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname><given-names>Y</given-names></name><name><surname>Kato</surname><given-names>N</given-names></name><name><surname>Hoshida</surname><given-names>Y</given-names></name><name><surname>Yoshida</surname><given-names>H</given-names></name><name><surname>Taniguchi</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>T</given-names></name><name><surname>Moriyama</surname><given-names>M</given-names></name><name><surname>Otsuka</surname><given-names>M</given-names></name><name><surname>Shiina</surname><given-names>S</given-names></name><name><surname>Shiratori</surname><given-names>Y</given-names></name><name><surname>Ito</surname><given-names>Y</given-names></name><name><surname>Omata</surname><given-names>M</given-names></name></person-group><article-title>Interleukin-1&#x003b2; gene polymorphisms associated with hepatocellular carcinoma in hepatitis C virus infection</article-title><source>Hepatology</source><year>2003</year><volume>37</volume><fpage>65</fpage><lpage>71</lpage><pub-id pub-id-type="pmid">12500190</pub-id><pub-id pub-id-type="doi">10.1053/jhep.2003.50017</pub-id></citation></ref><ref id="B27"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zienolddiny</surname><given-names>S</given-names></name><name><surname>Ryberg</surname><given-names>D</given-names></name><name><surname>Maggini</surname><given-names>V</given-names></name><name><surname>Skaug</surname><given-names>V</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><name><surname>Haugen</surname><given-names>A</given-names></name></person-group><article-title>Polymorphisms of the interleukin-1&#x003b2; gene are associated with increased risk of non-small cell lung cancer</article-title><source>Int J Cancer</source><year>2004</year><volume>109</volume><fpage>353</fpage><lpage>356</lpage><pub-id pub-id-type="pmid">14961572</pub-id><pub-id pub-id-type="doi">10.1002/ijc.11695</pub-id></citation></ref><ref id="B28"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Landi</surname><given-names>S</given-names></name><name><surname>Moreno</surname><given-names>V</given-names></name><name><surname>Gioia-Patricola</surname><given-names>L</given-names></name><name><surname>Guino</surname><given-names>E</given-names></name><name><surname>Navarro</surname><given-names>M</given-names></name><name><surname>de Oca</surname><given-names>J</given-names></name><name><surname>Capella</surname><given-names>G</given-names></name><name><surname>Canzian</surname><given-names>F</given-names></name><collab>Bellvitge Colorectal Cancer Study Group</collab></person-group><article-title>Association of common polymorphisms in inflammatory genes interleukin IL6, IL8, tumor necrosis factor-a, NFK B1, andperoxisome proliferator-activated receptor g with colorectal cancer</article-title><source>Cancer Res</source><year>2003</year><volume>63</volume><fpage>3560</fpage><lpage>3566</lpage><pub-id pub-id-type="pmid">12839942</pub-id></citation></ref><ref id="B29"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Berger</surname><given-names>I</given-names></name><name><surname>Tomovski</surname><given-names>C</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name><name><surname>Concin</surname><given-names>N</given-names></name><name><surname>Leodolter</surname><given-names>S</given-names></name><name><surname>Koelbl</surname><given-names>H</given-names></name><name><surname>Tempfer</surname><given-names>CB</given-names></name><name><surname>Hefler</surname><given-names>LA</given-names></name></person-group><article-title>A polymorphism of the interleukin-1 receptor antagonist plays a prominent role within the interleukin-1 gene cluster in vulvar carcinogenesis</article-title><source>Gynecol Oncol</source><year>2004</year><volume>92</volume><fpage>936</fpage><lpage>940</lpage><pub-id pub-id-type="pmid">14984963</pub-id><pub-id pub-id-type="doi">10.1016/j.ygyno.2003.11.039</pub-id></citation></ref><ref id="B30"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sehouli</surname><given-names>J</given-names></name><name><surname>Mustea</surname><given-names>A</given-names></name><name><surname>Koensgen</surname><given-names>D</given-names></name><name><surname>Chen</surname><given-names>FC</given-names></name><name><surname>Lichtenegger</surname><given-names>W</given-names></name></person-group><article-title>Interleukin-1 receptor antagonist gene polymorphism is associated with increased risk of epithelial ovarian cancer</article-title><source>Ann Oncol</source><year>2003</year><volume>14</volume><fpage>1501</fpage><lpage>1504</lpage><pub-id pub-id-type="pmid">14504049</pub-id><pub-id pub-id-type="doi">10.1093/annonc/mdg413</pub-id></citation></ref><ref id="B31"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Dominici</surname><given-names>R</given-names></name><name><surname>Cattaneo</surname><given-names>M</given-names></name><name><surname>Malferrari</surname><given-names>G</given-names></name><name><surname>Archi</surname><given-names>D</given-names></name><name><surname>Mariani</surname><given-names>C</given-names></name><name><surname>Grimaldi</surname><given-names>LM</given-names></name><name><surname>Biunno</surname><given-names>I</given-names></name></person-group><article-title>Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha</article-title><source>Immunogenetics</source><year>2002</year><volume>54</volume><fpage>82</fpage><lpage>6</lpage><pub-id pub-id-type="pmid">12037600</pub-id><pub-id pub-id-type="doi">10.1007/s00251-002-0445-9</pub-id></citation></ref><ref id="B32"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mul&#x000e9;</surname><given-names>JJ</given-names></name><name><surname>Custer</surname><given-names>M</given-names></name><name><surname>Averbook</surname><given-names>B</given-names></name><name><surname>Yang</surname><given-names>JC</given-names></name><name><surname>Weber</surname><given-names>JS</given-names></name><name><surname>Goeddel</surname><given-names>DV</given-names></name><name><surname>Rosenberg</surname><given-names>SA</given-names></name><name><surname>Schall</surname><given-names>TJ</given-names></name></person-group><article-title>RANTES secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations</article-title><source>Hum Gene Ther</source><year>1996</year><volume>7</volume><fpage>1545</fpage><lpage>1553</lpage><pub-id pub-id-type="pmid">8864755</pub-id><pub-id pub-id-type="doi">10.1089/hum.1996.7.13-1545</pub-id></citation></ref><ref id="B33"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duell</surname><given-names>EJ</given-names></name><name><surname>Casella</surname><given-names>DP</given-names></name><name><surname>Burk</surname><given-names>RD</given-names></name><name><surname>Kelsey</surname><given-names>KT</given-names></name><name><surname>Holly</surname><given-names>EA</given-names></name></person-group><article-title>Inflammation, genetic polymorphisms in proinflammatory genes TNF-A, RANTES, and CCR5, and risk of pancreatic adenocarcinoma</article-title><source>Cancer Epidemiol Biomarkers Prev</source><year>2006</year><volume>4</volume><fpage>726</fpage><lpage>731</lpage><pub-id pub-id-type="pmid">16614115</pub-id><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-05-0797</pub-id></citation></ref><ref id="B34"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Yoshimura</surname><given-names>T</given-names></name><name><surname>Robinson</surname><given-names>EA</given-names></name><name><surname>Tanaka</surname><given-names>S</given-names></name><name><surname>Appella</surname><given-names>E</given-names></name><name><surname>Kuratsu</surname><given-names>J</given-names></name><name><surname>Leonard</surname><given-names>EJ</given-names></name></person-group><article-title>Purification and amino acid analysis of two human glioma-derived monocyte chemoattractants</article-title><source>J Exp Med</source><year>1989</year><volume>169</volume><fpage>1449</fpage><lpage>1459</lpage><pub-id pub-id-type="pmid">2926329</pub-id><pub-id pub-id-type="doi">10.1084/jem.169.4.1449</pub-id></citation></ref><ref id="B35"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Roth</surname><given-names>SJ</given-names></name><name><surname>Carr</surname><given-names>MW</given-names></name><name><surname>Springer</surname><given-names>TA</given-names></name></person-group><article-title>C-C chemokines, but not the C-X-C chemokines interleukin-8 and interferon-&#x003b3; inducible protein-10, stimulate transendothelial chemotaxis of T lymphocytes</article-title><source>Eur J Immunol</source><year>1995</year><volume>25</volume><fpage>3482</fpage><lpage>488</lpage><pub-id pub-id-type="pmid">8566041</pub-id><pub-id pub-id-type="doi">10.1002/eji.1830251241</pub-id></citation></ref><ref id="B36"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ghilardi</surname><given-names>G</given-names></name><name><surname>Biondi</surname><given-names>ML</given-names></name><name><surname>La Torre</surname><given-names>A</given-names></name><name><surname>Battaglioli</surname><given-names>L</given-names></name><name><surname>Scorza</surname><given-names>R</given-names></name></person-group><article-title>Breast cancer progression and host polymorphisms in the chemokine system: role of the macrophage chemoattractant protein-1 (MCP-1) -2518 G allele</article-title><source>Clin Chem</source><year>2005</year><volume>51</volume><fpage>452</fpage><lpage>455</lpage><pub-id pub-id-type="pmid">15681563</pub-id><pub-id pub-id-type="doi">10.1373/clinchem.2004.041657</pub-id></citation></ref><ref id="B37"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Saji</surname><given-names>H</given-names></name><name><surname>Koike</surname><given-names>M</given-names></name><name><surname>Yamori</surname><given-names>T</given-names></name><name><surname>Saji</surname><given-names>S</given-names></name><name><surname>Seiki</surname><given-names>M</given-names></name><name><surname>Matsushima</surname><given-names>K</given-names></name><name><surname>Toi</surname><given-names>M</given-names></name></person-group><article-title>Significant correlation of monocyte chemoattractant protein-1 expression with neovascularization and progression of breast carcinoma</article-title><source>Cancer</source><year>2001</year><volume>92</volume><fpage>1085</fpage><lpage>1091</lpage><pub-id pub-id-type="pmid">11571719</pub-id><pub-id pub-id-type="doi">10.1002/1097-0142(20010901)92:5&#x0003c;1085::AID-CNCR1424&#x0003e;3.0.CO;2-K</pub-id></citation></ref><ref id="B38"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Liu</surname><given-names>H</given-names></name><name><surname>Chao</surname><given-names>D</given-names></name><name><surname>Nakayama</surname><given-names>EE</given-names></name><name><surname>Taguchi</surname><given-names>H</given-names></name><name><surname>Goto</surname><given-names>M</given-names></name><name><surname>Xin</surname><given-names>X</given-names></name><name><surname>Takamatsu</surname><given-names>JK</given-names></name><name><surname>Saito</surname><given-names>H</given-names></name><name><surname>Ishikawa</surname><given-names>Y</given-names></name><name><surname>Akaza</surname><given-names>T</given-names></name><name><surname>Juji</surname><given-names>T</given-names></name><name><surname>Takebe</surname><given-names>Y</given-names></name><name><surname>Ohishi</surname><given-names>T</given-names></name><name><surname>Fukutake</surname><given-names>K</given-names></name><name><surname>Maruyama</surname><given-names>Y</given-names></name><name><surname>Yashiki</surname><given-names>S</given-names></name><name><surname>Sonoda</surname><given-names>S</given-names></name><name><surname>Nakamura</surname><given-names>T</given-names></name><name><surname>Nagai</surname><given-names>Y</given-names></name><name><surname>Iwamoto</surname><given-names>A</given-names></name><name><surname>Shioda</surname><given-names>T</given-names></name></person-group><article-title>Polymorphism in RANTES chemokine promoter affects HIV-1 disease progression</article-title><source>Proc Natl Acad Sci USA</source><year>1999</year><volume>96</volume><fpage>4581</fpage><lpage>4585</lpage><pub-id pub-id-type="pmid">10200305</pub-id><pub-id pub-id-type="doi">10.1073/pnas.96.8.4581</pub-id></citation></ref><ref id="B39"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Rovin</surname><given-names>BH</given-names></name><name><surname>Lu</surname><given-names>L</given-names></name><name><surname>Saxena</surname><given-names>R</given-names></name></person-group><article-title>A novel polymorphism in the MCP-1 gene regulatory region that influences MCP-1 expression</article-title><source>Biochem Biophys Res Commun</source><year>1999</year><volume>259</volume><fpage>344</fpage><lpage>348</lpage><pub-id pub-id-type="pmid">10362511</pub-id><pub-id pub-id-type="doi">10.1006/bbrc.1999.0796</pub-id></citation></ref><ref id="B40"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Wilson</surname><given-names>AG</given-names></name><name><surname>Symons</surname><given-names>JA</given-names></name><name><surname>McDowell</surname><given-names>TL</given-names></name><name><surname>McDevitt</surname><given-names>HO</given-names></name><name><surname>Duff</surname><given-names>GW</given-names></name></person-group><article-title>Effects of a polymorphism in the human tumor necrosis factor a promoter on transcriptional activation</article-title><source>Proc Natl Acad Sci USA</source><year>1997</year><volume>94</volume><fpage>3195</fpage><lpage>3199</lpage><pub-id pub-id-type="pmid">9096369</pub-id><pub-id pub-id-type="doi">10.1073/pnas.94.7.3195</pub-id></citation></ref><ref id="B41"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fraile</surname><given-names>A</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name><name><surname>Bera&#x000fa;n</surname><given-names>Y</given-names></name><name><surname>Vinasco</surname><given-names>J</given-names></name><name><surname>Matar&#x000e1;n</surname><given-names>L</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name></person-group><article-title>Tumor necrosis factor gene polymorphisms in ankylosing spondylitis</article-title><source>Tissue Antigens</source><year>1998</year><volume>51</volume><fpage>386</fpage><lpage>390</lpage><pub-id pub-id-type="pmid">9583811</pub-id></citation></ref><ref id="B42"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nearman</surname><given-names>ZP</given-names></name><name><surname>Wlodarski</surname><given-names>M</given-names></name><name><surname>Jankowska</surname><given-names>AM</given-names></name><name><surname>Howe</surname><given-names>E</given-names></name><name><surname>Narvaez</surname><given-names>Y</given-names></name><name><surname>Ball</surname><given-names>E</given-names></name><name><surname>Macijewski</surname><given-names>JP</given-names></name></person-group><article-title>Immunogenetic factors determining the evolution of T-cell large granular lymphocyte leukaemia and associated cytopenias</article-title><source>Br J Haematol</source><year>2007</year><volume>136</volume><fpage>237</fpage><lpage>248</lpage><pub-id pub-id-type="pmid">17156396</pub-id><pub-id pub-id-type="doi">10.1111/j.1365-2141.2006.06429.x</pub-id></citation></ref><ref id="B43"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Ho</surname><given-names>SY</given-names></name><name><surname>Wang</surname><given-names>YJ</given-names></name><name><surname>Huang</surname><given-names>PC</given-names></name><name><surname>Tsai</surname><given-names>ST</given-names></name><name><surname>Chen</surname><given-names>CH</given-names></name><name><surname>Chen</surname><given-names>HH</given-names></name><name><surname>Chang</surname><given-names>CJ</given-names></name><name><surname>Guo</surname><given-names>HR</given-names></name></person-group><article-title>Evaluation of the associations between the single nucleotide polymorphisms of the promoter region of the tumor necrosis factor-alpha gene and nasopharyngeal carcinoma</article-title><source>J Chin Med Assoc</source><year>2006</year><volume>69</volume><fpage>351</fpage><lpage>357</lpage><pub-id pub-id-type="pmid">16970270</pub-id></citation></ref><ref id="B44"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Govan</surname><given-names>VA</given-names></name><name><surname>Constant</surname><given-names>D</given-names></name><name><surname>Hoffman</surname><given-names>M</given-names></name><name><surname>Williamson</surname><given-names>AL</given-names></name></person-group><article-title>The allelic distribution of -308 Tumor Necrosis Factor-alpha gene polymorphism in South African women with cervical cancer and control women</article-title><source>BMC Cancer</source><year>2006</year><volume>26</volume><fpage>24</fpage><pub-id pub-id-type="pmid">16438713</pub-id><pub-id pub-id-type="doi">10.1186/1471-2407-6-24</pub-id></citation></ref><ref id="B45"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gelmann</surname><given-names>EP</given-names></name></person-group><article-title>Complexities of prostate-cancer risk</article-title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>961</fpage><lpage>3</lpage><pub-id pub-id-type="pmid">18199856</pub-id><pub-id pub-id-type="doi">10.1056/NEJMe0708703</pub-id></citation></ref><ref id="B46"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Oliver</surname><given-names>J</given-names></name><name><surname>G&#x000f3;mez-Garc&#x000ed;a</surname><given-names>M</given-names></name><name><surname>Paco</surname><given-names>L</given-names></name><name><surname>L&#x000f3;pez-Nevot</surname><given-names>MA</given-names></name><name><surname>Pi&#x000f1;ero</surname><given-names>A</given-names></name><name><surname>Correro</surname><given-names>F</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>L</given-names></name><name><surname>Brieva</surname><given-names>JA</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name></person-group><article-title>A functional polymorphism of the NFKB1 promoter is not associated with ulcerative colitis in a Spanish population</article-title><source>Inflamm Bowel Dis</source><year>2005</year><volume>11</volume><fpage>576</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">15905705</pub-id><pub-id pub-id-type="doi">10.1097/01.MIB.0000161916.20007.76</pub-id></citation></ref><ref id="B47"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>J</given-names></name><name><surname>Wiklund</surname><given-names>F</given-names></name><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>B&#x000e4;lter</surname><given-names>K</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Johansson</surname><given-names>JE</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name><name><surname>Liu</surname><given-names>W</given-names></name><name><surname>Tolin</surname><given-names>A</given-names></name><name><surname>Turner</surname><given-names>AR</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gr&#x000f6;nberg</surname><given-names>H</given-names></name></person-group><article-title>Sequence variants in Toll-like receptor gene cluster (<italic>TLR6 </italic>-<italic>TLR1</italic>-<italic>TLR10</italic>) and prostate cancer risk</article-title><source>J Natl Cancer Inst</source><year>2005</year><volume>97</volume><fpage>525</fpage><lpage>532</lpage><pub-id pub-id-type="pmid">15812078</pub-id></citation></ref><ref id="B48"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>SL</given-names></name><name><surname>Augustsson-B&#x000e4;lter</surname><given-names>K</given-names></name><name><surname>Chang</surname><given-names>B</given-names></name><name><surname>Hedelin</surname><given-names>M</given-names></name><name><surname>Li</surname><given-names>L</given-names></name><name><surname>Adami</surname><given-names>HO</given-names></name><name><surname>Bensen</surname><given-names>J</given-names></name><name><surname>Li</surname><given-names>G</given-names></name><name><surname>Johnasson</surname><given-names>JE</given-names></name><name><surname>Turner</surname><given-names>AR</given-names></name><name><surname>Adams</surname><given-names>TS</given-names></name><name><surname>Meyers</surname><given-names>DA</given-names></name><name><surname>Isaacs</surname><given-names>WB</given-names></name><name><surname>Xu</surname><given-names>J</given-names></name><name><surname>Gr&#x000f6;nberg</surname><given-names>H</given-names></name></person-group><article-title>Sequence variants of toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study</article-title><source>Cancer Res</source><year>2004</year><volume>64</volume><fpage>2918</fpage><lpage>2922</lpage><pub-id pub-id-type="pmid">15087412</pub-id><pub-id pub-id-type="doi">10.1158/0008-5472.CAN-03-3280</pub-id></citation></ref><ref id="B49"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>El-Omar</surname><given-names>EM</given-names></name><name><surname>Carrington</surname><given-names>M</given-names></name><name><surname>Chow</surname><given-names>WH</given-names></name><name><surname>McColl</surname><given-names>KE</given-names></name><name><surname>Bream</surname><given-names>JH</given-names></name><name><surname>Young</surname><given-names>HA</given-names></name><name><surname>Herrera</surname><given-names>J</given-names></name><name><surname>Lissowska</surname><given-names>J</given-names></name><name><surname>Yuan</surname><given-names>CC</given-names></name><name><surname>Rothman</surname><given-names>N</given-names></name><name><surname>Lanyon</surname><given-names>G</given-names></name><name><surname>Martin</surname><given-names>M</given-names></name><name><surname>Fraumeni</surname><given-names>JF</given-names><suffix>Jr</suffix></name><name><surname>Rabkin</surname><given-names>CS</given-names></name></person-group><article-title>Interleukin-1 polymorphisms associated with increased risk of gastric cancer</article-title><source>Nature</source><year>2000</year><volume>404</volume><fpage>398</fpage><lpage>402</lpage><pub-id pub-id-type="pmid">10746728</pub-id><pub-id pub-id-type="doi">10.1038/35006081</pub-id></citation></ref><ref id="B50"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hefler</surname><given-names>LA</given-names></name><name><surname>Ludwig</surname><given-names>E</given-names></name><name><surname>Lebrecht</surname><given-names>A</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name><name><surname>Tong-Cacsire</surname><given-names>D</given-names></name><name><surname>Koelbl</surname><given-names>H</given-names></name><name><surname>Leodolter</surname><given-names>S</given-names></name><name><surname>Tempfer</surname><given-names>CB</given-names></name></person-group><article-title>Polymorphisms of the interleukin-1 gene cluster and ovarian cancer</article-title><source>J Soc Gynecol Investig</source><year>2002</year><volume>9</volume><fpage>386</fpage><lpage>90</lpage><pub-id pub-id-type="pmid">12445604</pub-id><pub-id pub-id-type="doi">10.1016/S1071-5576(02)00177-6</pub-id></citation></ref><ref id="B51"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hefler</surname><given-names>LA</given-names></name><name><surname>Grimm</surname><given-names>C</given-names></name><name><surname>Lantzsch</surname><given-names>T</given-names></name><name><surname>Lampe</surname><given-names>D</given-names></name><name><surname>Leodolter</surname><given-names>S</given-names></name><name><surname>Koelbl</surname><given-names>H</given-names></name><name><surname>Heinze</surname><given-names>G</given-names></name><name><surname>Reinthaller</surname><given-names>A</given-names></name><name><surname>Tong-Cacsire</surname><given-names>D</given-names></name><name><surname>Tempfer</surname><given-names>C</given-names></name><name><surname>Zeillinger</surname><given-names>R</given-names></name></person-group><article-title>Interleukin-1 and interleukin-6 gene polymorphisms and the risk of breast cancer in caucasian women</article-title><source>Clin Cancer Res</source><year>2005</year><volume>11</volume><fpage>5718</fpage><lpage>21</lpage><pub-id pub-id-type="pmid">16115908</pub-id><pub-id pub-id-type="doi">10.1158/1078-0432.CCR-05-0001</pub-id></citation></ref><ref id="B52"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kamangar</surname><given-names>F</given-names></name><name><surname>Cheng</surname><given-names>C</given-names></name><name><surname>Abnet</surname><given-names>CC</given-names></name><name><surname>Rabkin</surname><given-names>CS</given-names></name></person-group><article-title>Interleukin-1B polymorphisms and gastric cancer risk&#x02013;a meta-analysis</article-title><source>Cancer Epidemiol Biomarkers</source><year>2006</year><volume>15</volume><fpage>1920</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1158/1055-9965.EPI-06-0267</pub-id></citation></ref><ref id="B53"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Mule</surname><given-names>JJ</given-names></name><name><surname>Custer</surname><given-names>M</given-names></name><name><surname>Averbook</surname><given-names>B</given-names></name><etal></etal></person-group><article-title>Rantes secretion by gene-modified tumor cells results in loss of tumorigenicity in vivo: role of immune cell subpopulations</article-title><source>Hum Gene Ther</source><year>1996</year><volume>7</volume><fpage>1545</fpage><lpage>53</lpage><pub-id pub-id-type="pmid">8864755</pub-id><pub-id pub-id-type="doi">10.1089/hum.1996.7.13-1545</pub-id></citation></ref><ref id="B54"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>S&#x000e1;nchez</surname><given-names>E</given-names></name><name><surname>Sabio</surname><given-names>JM</given-names></name><name><surname>Callejas</surname><given-names>JL</given-names></name><name><surname>de Ram&#x000f3;n</surname><given-names>E</given-names></name><name><surname>Garcia-Portales</surname><given-names>R</given-names></name><name><surname>Garc&#x000ed;a-Hern&#x000e1;ndez</surname><given-names>FJ</given-names></name><name><surname>Jim&#x000e9;nez-Alonso</surname><given-names>J</given-names></name><name><surname>Gonz&#x000e1;lez-Escribano</surname><given-names>MF</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name><name><surname>Koeleman</surname><given-names>BP</given-names></name></person-group><article-title>Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus</article-title><source>BMC Med Genet</source><year>2006</year><volume>7</volume><fpage>48</fpage><pub-id pub-id-type="pmid">16719905</pub-id><pub-id pub-id-type="doi">10.1186/1471-2350-7-48</pub-id></citation></ref><ref id="B55"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Vinasco</surname><given-names>J</given-names></name><name><surname>Bera&#x000fa;n</surname><given-names>Y</given-names></name><name><surname>Nieto</surname><given-names>A</given-names></name><name><surname>Fraile</surname><given-names>A</given-names></name><name><surname>Mataran</surname><given-names>L</given-names></name><name><surname>Pareja</surname><given-names>E</given-names></name><name><surname>Mart&#x000ed;n</surname><given-names>J</given-names></name></person-group><article-title>Polymorphism at the TNF loci in rheumatoid arthritis</article-title><source>Tissue Antigens</source><year>1997</year><volume>49</volume><fpage>74</fpage><lpage>8</lpage><pub-id pub-id-type="pmid">9027971</pub-id><pub-id pub-id-type="doi">10.1111/j.1399-0039.1997.tb02715.x</pub-id></citation></ref><ref id="B56"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Lio</surname><given-names>D</given-names></name><name><surname>Scola</surname><given-names>L</given-names></name><name><surname>Crivello</surname><given-names>A</given-names></name><name><surname>Colonna-Romano</surname><given-names>G</given-names></name><name><surname>Candore</surname><given-names>G</given-names></name><name><surname>Bonaf&#x000e9;</surname><given-names>M</given-names></name><name><surname>Cavallone</surname><given-names>L</given-names></name><name><surname>Marchegiani</surname><given-names>F</given-names></name><name><surname>Olivieri</surname><given-names>F</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name><name><surname>Caruso</surname><given-names>C</given-names></name></person-group><article-title>Inflammation, genetics, and longevity: further studies on the protective effects in men of IL-10 -1082 promoter SNP and its interaction with TNF-alpha -308 promoter SNP</article-title><source>J Med Genet</source><year>2003</year><volume>40</volume><fpage>296</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">12676903</pub-id><pub-id pub-id-type="doi">10.1136/jmg.40.4.296</pub-id></citation></ref><ref id="B57"><citation citation-type="journal"><person-group person-group-type="author"><name><surname>Cardelli</surname><given-names>M</given-names></name><name><surname>Cavallone</surname><given-names>L</given-names></name><name><surname>Marchegiani</surname><given-names>F</given-names></name><name><surname>Oliveri</surname><given-names>F</given-names></name><name><surname>Dato</surname><given-names>S</given-names></name><name><surname>Montesanto</surname><given-names>A</given-names></name><name><surname>Lescai</surname><given-names>F</given-names></name><name><surname>Lisa</surname><given-names>R</given-names></name><name><surname>De Benedictis</surname><given-names>G</given-names></name><name><surname>Franceschi</surname><given-names>C</given-names></name></person-group><article-title>A genetic-demographic approach reveals male-specific association between survival and tumor necrosis factor (A/G)-308 polymorphism</article-title><source>J Gerontol A Biol Sci Med Sci</source><year>2008</year><volume>63</volume><fpage>454</fpage><lpage>60</lpage><pub-id pub-id-type="pmid">18511747</pub-id></citation></ref></ref-list></back></article> 